Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01520233|
Recruitment Status : Completed
First Posted : January 27, 2012
Last Update Posted : May 17, 2016
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and predict how patients will respond to treatment. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in predicting outcomes in samples from patients with high-risk neuroblastoma.
|Condition or disease||Intervention/treatment|
|Neuroblastoma||Genetic: RNA analysis Genetic: gene expression analysis Other: laboratory biomarker analysis|
- To test the correlation of a previously published microarray gene expression signature with the gene expression obtained with the nCounter™ Analysis System using RNA isolated from formalin-fixed, paraffin-embedded (FFPE), high-risk neuroblastoma samples.
- To construct, test, and validate a novel robust classifier that can be readily integrated into the clinic.
OUTLINE: This is a multicenter study.
RNA samples extracted from paraffin-embedded tissue are analyzed for gene signature expression levels by nCounter™ Analysis System and correlated with published microarray expression data. Results are then used to develop a refined gene-expression-profile classifier of ultra high-risk neuroblastoma.
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||Genome Based Outcome Prediction in High Risk Neuroblastoma|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
- Linear correlation between the nCounter™ Analysis System and the expression data obtained in microarray platforms
- nCounter™ Analysis System and microarray platforms equally predictive of outcome in the high-risk group of neuroblastoma patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01520233
|Principal Investigator:||Susan L. Cohn, MD||University of Chicago Comer Children's Hospital|